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A B S T R A C T
Purpose: The aim of this study is to describe seizure as a presenting symptom in individualswith recently
diagnosed neurocysticercosis (NCC).
Methods: Using logistic regression, we examined the probability of having seizures as a presenting
symptom among those with active or transitional NCC by host age and gender, and by number of cysts,
location of the cysts in the brain, and phase of evolution of the encysted parasite.
Results: We found that the odds of having seizures as presenting symptom for those in the youngest age
group (3–24 years old) were 12.9 times that of the oldest participants (age 55–82 years) (p = 0.006).
People with cysts in parenchymal locations had a significantly higher odds of seizures compared to those
with all their cysts elsewhere (ventricles or subarachnoid) (OR = 6.2, p = 0.028); and the number of cysts
was significantly associated with having seizures (OR = 1.1, p = 0.026). Host gender and cyst phase were
not significantly associated with having seizures after adjusting for confounders and covariates.
Conclusion: Children, thosewith cysts in parenchymal locations, and thosewith a higher number of cysts
appear to be more likely to experience seizure when they have NCC cysts in the active or transitional
stage.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
journal homepage: www.e lsev ier .com/ locate /yse iz1. Introduction
Neurocysticercosis (NCC) is an infection of the central nervous
system (CNS) with the larval stage of the intestinal pork tapeworm
Taenia solium (T. solium). Humans become infected with the larval
form of the parasite through the fecal–oral route by ingesting* Corresponding author. Tel.: +1 212 481 4764; fax: +1 212 543 6002.
E-mail addresses: ekelvin@hunter.cuny.edu, eak34@columbia.edu (E.A. Kelvin).
1 The members of the Ecuadorian Neurocysticercosis Group are: Noemi Lisanti
M.D. (‘‘Comprehensive Epilepsy Center’’, Cuenca), Consultorios Me´dicos Santa Ana,
Av. 12 de Abril y Av. Paucarbamba, Cuenca, Ecuador; Rafael Aguirre M.D. (‘‘Teodoro
Maldonado’’ Hospital, Guayaquil), Clinica Panamericana. Panama 6-16 Y Roca,
Guayaquil, Ecuador;Marcos SerranoM.D. (‘‘Carlos AndradeMarı´n’’ Hospital, Quito),
Av. Eloy Alfaro N29-143 e Inglaterra. Edificio Salazar Barba 4to. Piso. Quito, Ecuador;
Jorge Pesantes M.D. (‘‘Eugenio Espejo’’ Hospital, Quito). Consultorio Me´dico
Pichincha, Vintimilla 10-78 Y Pa´ez Quito, Ecuador.; Jorge Moncayo M.D. (‘‘Eugenio
Espejo’’ Hospital, Quito), Servicio de Neurologı´a. Hospital Eugenio Espejo, Quito,
Ecuador; and Marcelo Roman M.D. (‘‘Baca Ortiz’’ Hospital, Quito). Centro Me´dico
Axis Calle Vozandes 2-60 y Av. Ame´rica, Quito, Ecuador.
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.10.036parasite eggs from a human harboring an adult tapeworm in the
intestines.1 While the larval form of the parasite can reside in
almost any human tissue,2 it has an affinity for nervous system
tissue,3,4 where it forms a cyst enclosing the parasite. The encysted
parasite progresses through three distinct phases of evolution: (1)
the active phase, in which the parasite is alive, (2) the transitional
phase, in which the parasite has begun to degenerate and is being
attacked by the host’s immune system, and (3) the inactive phase,
in which the parasite is deceased but has left a calcified nodule.5
NCC is possibly the most heterogeneous infection of the CNS,
with a wide variety of clinical manifestations.6–9 However, the
most common symptom is seizure.4,10–14 Reports suggest that
seizures are themost frequentmanifestation of cysts located in the
brain parenchyma;3,15–21 and seizures have been reported in
patients with cysts in all three phases of evolution (active,
transitional, and inactive).4,12 Seizures associated with cysts in the
transitional stage, characterized by edema surrounding the
degenerating cyst, are considered to be provoked or acute
symptomatic. Seizures associated with active or inactive cystsvier Ltd. All rights reserved.
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seizures through residual perilesional gliosis,23 or scarring,12 that
results in a chronic epileptogenic foci.4
Generalized seizures and partial seizures with secondary
generalization are the most common types experienced by people
with NCC; and only a minority of those infected with NCC present
with complex partial seizures.4,12,14,15,23 It has been suggested that
the low frequency of complex partial seizures in those with NCC is
due to the high proportion of NCC patients with cysts in the parietal
and frontal lobesand the relatively smallerproportionwith temporal
lobe cysts.23 However, a thorough examination of seizure in NCC
patients by the location and phase of the cysts has not been done.
The aim of this investigation is to examine seizures as a
presenting symptom in people diagnosed with NCC in detail. We
compared the probability having seizures as a presenting symptom
among symptomatic NCC patients by host age and gender, by
location of the cysts in the brain, and by phase of evolution of the
parasite. We also describe seizure classification by patient age and
gender and cyst location and phase.
2. Methods
2.1. Study design and subjects
The data described in this paper come from the baseline
assessment of participants of a clinical trial of treatment for
symptomatic NCC infection conducted in Ecuador between 2001
and 2003.24 For this trial, individuals with newly diagnosed NCC
were randomized to receive symptomatic treatment plus alben-
dazole or symptomatic treatment plus placebo. NCC patients were
eligible to participate in the study if they presentedwith new onset
of symptoms associated with NCC within the past 2 months and
had active and/or transitional NCC cysts apparent on CT or MRI.
Patients with only inactive NCC cysts were not eligible to
participate in the study. In addition, those who were pregnant,
had active tuberculosis, syphilis, papilledema, ocular cysticercosis,
active ulcers, or some other progressive and life threatening
disorder were also considered ineligible. Partway through the
study we also excluded patients with ventricular shunt for safety
reasons due to the poor outcome of shunted NCC patients. Finally,
patients who had received treatment for NCC during the past year
or who had undergone systemic treatment with steroids within 30
days of presentation were ineligible for this study.
2.2. Data collection
At enrollment into the study, we collected basic demographic
information, including participant’s age and gender, as well as
information about all health problems experienced during the 2
months prior to study enrollment through the reading of a
symptom checklist. Patients who reported having had seizures
during this time period were then asked to describe each seizure.
Based on the patient’s description, the seizures were classified
according to the International League Against Epilepsy categories:
Partial not specified, simple partial, complex partial, partial with
secondary generalization, and generalized.25
A CT or MRI taken no more than 2 weeks prior to study
enrollment was read by two neuroradiologists, one in Ecuador and
one in the United States (US). The cysts were categorized according
to location within the brain and phase of evolution as defined by
Carpio et al.5 Cyst phase was classified as active, transitional, or
inactive. Although patients with only inactive cysts were ineligible
for this study, many of the patients with active or transitional cysts
also had inactive cysts. In addition, racemous cysts, or clusters,
which can include cysts in both the active and transitional phase,
were enumerated and analyzed as a separate group. The inter-raterreliability of the scan readings was acceptable, with kappas
ranging from 0.4 to 0.7 for identifying that a patient had cysts in a
specific location or phase of evolution. The readings of the US
radiologist are used in these analyses.
A written informed consent form for study participation was
signed by all participants or, in the case of participants under 18
years old, by their legal guardian. Participants under 18 years old
also provided oral assent for participation. Approval for the study
was granted by the Columbia University Institutional Review
Board, the Office for Protection from Research Risks (OPRR) of
National Institutes of Health, as well as the Ethics Committees at
the participating hospitals in Ecuador.
2.3. Statistical analysis
Data were processed and statistics generated using SPSS 16.0
(Chicago, Illinois).We examined seizure status by characteristics of
the patient and of the infection (host age and gender, cyst location
and phase). We categorized patients according to the presence of
NCC cysts in the specified location (parenchymal, subarachnoid,
and intraventricular) and phase group (active, transitional,
inactive, and cluster). All clusters, whether in the active or
transitional phase, were included only in the cluster category. The
location and phase categories were examined in two ways, first as
an indicator for the presence of any cysts in the specified location
or phase, in which patients could have cysts in more than one
category of phase or location (i.e. the categories were not mutually
exclusive). We also constructed categorical variables for location
and phase comparing those with only cysts in the specified
location or phase to those without such cysts (mutually exclusive
categories). Because we excluded patients who had only calcified
cysts from the clinical trial, we are not able to examine the
association of having only calcified cysts with seizure. For the
analyses regarding seizure classification, we used the description
of the seizure that occurred closest to the time of the interview in
order to reduce misclassification due to recall errors.
We used the Pearson chi-squared statistic to assess statistical
significance when examining the frequency of categorical vari-
ables. When one or more cell in a table had an expected count of
less than 5, the Fisher’s exact test was used for assessing statistical
significance. The number of seizures, which is not normally
distributed, was examined using nonparametric methods, specifi-
cally the Mann–Whitney U or Kruskal–Wallis tests.
Logistic regression models were run to assess the association of
having seizures as a presenting symptom with patient age and
gender and with cyst location (parenchymal, subarachnoid and
intraventricular) and phase (active, transitional, cluster and
inactive) while controlling for covariates and potential confoun-
ders. Again, we modeled cyst location and phase in two ways. First
we ran the model with the non-mutually exclusive indicators for
having any cysts in the specific location of phase. Second we
created mutually exclusive dummy variables for cyst location
(only parenchymal cysts, only extraparenchymal cysts, both
parenchymal and extraparenchymal cysts) and phase (only active
cysts, only transitional cysts, only clusters, cyst in more than one
phase). There were too few participants with only subarachnoid
cysts and only intraventricular cysts to examine these locations
separately and therefore the two locations were combined into a
dummy variable for having only extraparenchymal cysts. In
addition, as mentioned above, we have no study participants with
only calcified cysts and therefore those participants are included in
the group with cysts in more than one phase. The reference
category used for cyst location was extraparenchymal cysts, and
the reference category for cyst phase was active cysts.
We also examined three indicators for economic and physical
barriers to healthcare access as potential confounders, as they may
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severe than seizures. Specifically, we looked at: patient’s monthly
household income, whichmay determine the ability to pay for, and
therefore receive care; the distance of patient’s residence from a
paved road, and location of the patient’s residence in the same
province as the treating hospital, both of which may influence
physical access to a tertiary care hospital with facilities for
diagnosing and treating NCC. We also adjusted for type of image
(CT or MRI) because transitional cysts are easier to identify in MRI
than CT.26 Therefore measurement error rates will differ depend-
ing on which type of image is being read. In addition, we examined
the total number of cysts, and therefore the regression analyses
excluded patients with too many cysts to count, which was
determined to be more than 49 cysts by our neuroradiologists.
3. Results
3.1. Description of sample and distribution of seizures (Table 1)
A total of 172 neurocysticercosis patients enrolled in the study,
56% of whomweremale. The age range was 3–82 years. Half of the
participants had a CT scan (n = 86) and half an MRI (n = 86) taken,
from which NCC was diagnosed and details about the cysts were
collected. A total of 107 patients reported having new onset of
seizures within 2 months of enrollment. There was no significant
difference in the type of image taken (CT versus MRI) by seizure
status (54.7% of those with seizures and 45.3% of those without
seizures had a CT scan, chi-square p = 0.068). Those who had
seizures had had an average of 3.4 seizures in the previous 2
months.
There was no difference in the proportion of men and women
having seizures (p = 0.819), and among those who had seizures
there was no gender difference in the number of seizures
experienced in the past 2 months (p = 0.479). The age groups
were similar in terms of the proportion experiencing seizures, with
the exception of patients age 3–19 years old, of whom all (100%)
had seizures (p = 0.004). Among those who had seizures, there was
no significant age-difference in the number of seizures experi-
enced in the past 2 months (p = 0.819).
We had a baseline scan on 170 patients. Patients with
transitional cysts were significantly more likely to have seizures
compared to patients with no transitional cysts (69.6% versus
50.0%, p = 0.010), and among those who had seizures, those with
transitional cysts had significantly more seizures in the past 2
months (p = 0.032). Patients with clusters (all of which were extra-
axial) were significantly less likely to have seizures (31.0% versus
68.1%, p = 0.000). There was no significant difference in the
probability of having seizures or, among thosewho had seizures, in
the number of seizures experienced in the previous 2 months,
among those with active cysts compared to those without such
cysts. The presence of inactive cysts was also not associated with
the probability of having seizures or with the number of seizures
experienced.
Patients with parenchymal cysts were significantly more likely
to have seizures compared to patients without parenchymal cysts
(67.8% versus 26.1%, p = 0.000). Patients with cysts in the parietal
lobe (69.3 versus 50.7, p = 0.014) or occipital lobe (72.1% versus
56.0%, p = 0.037) were also more likely to have seizures compared
to patients without any cysts in that location. Patients with
subarachnoid cysts were significantly less likely to have seizures
compared to patients without subarachnoid cysts (42.3% versus
75.8%, p = 0.000). Among those who had seizures, there was no
significant difference in the number of seizures experienced by
cyst location.
Limiting the comparisons to patients with only cysts in the
specified location or phase compared to those without cysts in thatlocation or phase did not change the results, except that the
increased probability of reporting seizures by patientswith cysts in
the frontal lobe became statistically significant (92.3% versus
53.5%, p = 0.009), and the association of seizures with cysts in the
occipital lobe was no longer statistically significant (80.0% versus
56.0%, p = 0.389), probably due to the small number of patients
with only occipital lobe cysts (n = 5).
We further examined the patients under age 20 years in an
attempt to determine if one possible explanation for the high
proportion (100%) of that group experiencing seizure was that they
had new onset idiopathic epilepsy (presumed genetic) with the
NCC cysts being discovered coincidentally when the seizure cause
was investigated. Of the 19 patients age 0–19 years for whom we
had scan data, 15 (78.9%) had only transitional cysts, while 4 had
only active cysts; 18 of the 19 patients had parenchymal cysts and
one had both intraventricular and subarachnoid cysts. The
majority of these patients had only 1 cyst (n = 15), while one
patient had 4 cysts, one had 33 cysts and two patients had too
many cysts to count (>49). Looking at the 6 patients under 11 years
old, 5 had only 1 transitional cyst, while 1 had more than 50 active
cysts and all the cysts in this group were parenchymal cysts. Thus
the majority of the patients in the youngest age group have
provoked seizures (associated with transitional cysts) and
parenchymal cysts.
3.2. Logistic regression models (Table 2)
Because all patients under age 20 years had seizures, we
expanded the youngest age group to patients age 3–24 for the
regression models, and then adjusted the other age groups into
approximate 10-year intervals to maintain a sufficient number
within each category. In the adjusted logistic regression model
controlling for having any cysts in each location and phase (non-
mutually exclusive indicators) as well as measures of healthcare
access, type of image (CT or MRI), and number of NCC cysts,
patients under age 25 years had an odds of seizure that was 12.6
times that of patients over age 55 years (p = 0.007). There were no
other significant differences in the odds of having seizures by age
group, nor was there any significant gender difference.
In that same adjusted logistic regression model, there was no
significant association between seizure and having any cysts in a
specific phase. However, patients with cysts in the brain
parenchyma had an odds of seizures that was 6.1 times higher
than that of patients without parenchymal cysts (p = 0.030), while
patients with subarachnoid cysts had a significantly lower odds of
seizure compared to patients without subarachnoid cysts
(OR = 0.3, p = 0.020). The total number of cysts was also
significantly associated with the odds of having seizure such that
for each additional NCC cyst, the odds of seizures increased by 10%
(p = 0.028).
When the cysts were examined as mutually exclusive catego-
ries for phase (only active cysts, only transitional cysts, only
clusters, or cysts in more than one phase) and location (only
parenchymal cysts, only extraparenchymal cysts, or cysts in both
parenchymal and extraparenchymal regions), the conclusions
were the same. Those aged 3–24 years had a significantly higher
odds of having seizure compared to those aged 55–82 years
(OR = 7.5, p = 0.018), those with only parenchymal cysts had a
higher odds of seizure than those with only extraparenchymal
cysts (OR = 3.9, p = 0.005), and total number of cysts was positively
associated with seizure (OR = 1.1, p = 0.015).
3.3. Seizure classification (Table 3)
Of the 107 patients who reported seizures at baseline, 44 had
had only one seizure. Of the 63 patients who had had more than
Table 1
Seizures by gender and age of patient and phase and location of cysts.
Variable Total
number (%)
Number (%)
with seizures
p-value for
Pearson
chi-square test
Mean number
of seizures (SD)
among those
who had seizures
p-value
for non-
parametric test
Patient demographic characteristics
Total 172 (100) 107 (62.2) 3.4 (4.2)
Gender 0.819 0.479a
Male 96 (55.8) 59 (61.5) 2.9 (3.2)
Female 76 (44.2) 48 (63.2) 4.0 (5.2)
Age (years) 0.004 0.819b
3–19 20 (11.6) 20 (100) 3.7 (5.7)
20–29 32 (18.6) 20 (62.5) 3.2 (4.3)
30–39 34 (19.8) 20 (58.8) 3.4 (3.1)
40–49 42 (24.4) 25 (59.5) 3.5 (4.0)
50–82 44 (25.6) 22 (50.0) 3.1 (4.3)
NCC cyst phase and location: presence of one or more cysts in specified phase or location
Cyst phase
Presence of active cysts 102 (60.0) 59 (57.8) 0.198 2.9 (3.7) 0.105a
No active cysts 68 (40.0) 46 (67.6) 4.1 (4.9)
Presence of transitional cysts 102 (60.0) 71 (69.6) 0.010 3.8 (4.6) 0.032a
No Transitional cysts 68 (40.0) 34 (50.0) 2.6 (3.5)
Presence of clusters 29 (17.1) 9 (31.0) 0.000 3.0 (1.2) 0.194a
No clusters 141 (82.9) 96 (68.1) 3.5 (4.5)
Presence of inactive/calcifications 70 (41.2) 45 (64.3) 0.571 3.3 (4.7) 0.309a
No inactive/calcifications 100 (58.8) 60 (60.0) 3.5 (3.9)
NCC cyst phase and location: presence of one or more cysts in specified phase or location
Cyst location
Presence of subarachnoid cysts 71 (41.8) 30 (42.3) 0.000 3.2 (3.5) 0.344a
No subarachnoid cysts 99 (58.2) 75 (75.8) 3.5 (4.6)
Presence of intraventricular cysts 17 (10.0) 7 (41.2) 0.066 1.7 (1.1) 0.197a
No intraventricular cysts 153 (90.0) 98 (64.1) 3.6 (4.4)
Presence of parenchymal cysts 147 (86.5) 99 (67.3) 0.000 3.5 (4.4) 0.499a
No parenchymal cysts 23 (13.5) 6 (26.1) 1.8 (0.8)
Presence of frontal lobe cysts 99 (58.2) 67 (67.7) 0.061 3.3 (4.1) 0.576a
No frontal lobe cysts 71 (41.8) 38 (53.5) 3.7 (4.6)
Presence of temporal lobe cysts 88 (51.8) 52 (59.1) 0.457 2.9 (3.4) 0.328a
No temporal lobe cysts 82 (48.2) 53 (64.6) 3.9 (5.0)
Presence of parietal lobe cysts 101 (59.4) 70 (69.3) 0.014 3.6 (4.6) 0.815a
No parietal lobe cysts 69 (40.6) 35 (50.7) 3.1 (3.6)
Presence of occipital lobe cysts 61 (35.9) 44 (72.1) 0.037 3.8 (4.8) 0.443a
No occipital lobe cysts 109 (64.1) 61 (56.0) 3.2 (3.9)
Presence of basal ganglia and internal capsule cysts 52 (39.6) 34 (65.4) 0.519 2.7 (3.4) 0.330a
No basal ganglia and internal capsule cysts 118 (69.4) 71 (60.2) 3.8 (4.6)
NCC cyst phase and location: presence of cysts only in specified phase or location
Cysts phase
Only active cysts 28 (29.2) 13 (46.4) 0.052 2.5 0.283a
No active cysts 68 (70.8) 46 (67.6) 4.1
Only transitional cysts 45 (39.8) 37 (82.2) 0.001 4.1 0.042a
No transitional cysts 68 (60.2) 34 (50.0) 2.6
NCC cyst phase and location: presence of cysts only in specified phase or location
Cysts phase
Only clusters 10 (6.6) 2 (10.0) 0.004c 2.5 0.656a
No clusters 141 (93.4) 96 (68.1) 3.5
Cyst location
Only subarachnoid cysts 17 (14.7) 2 (11.8) 0.000 2.5 0.579a
No subarachnoid cysts 99 (85.3) 75 (75.8) 3.5
Only intraventricular cysts 2 (1.3) 1 (50.0) 1.000c 1.0 0.283a
No intraventricular cysts 153 (98.7) 98 (64.1) 3.6
Only parenchymal cysts 91 (79.8) 69 (75.8) 0.000 3.7 0.602a
No parenchymal cysts 23 (20.2) 6 (26.1) 1.8
Only frontal lobe cysts 13 (15.5) 12 (92.3) 0.009 2.9 0.842a
No frontal lobe cysts 71 (84.5) 38 (53.5) 3.7
Only temporal lobe cysts 9 (9.9) 5 (55.6) 0.718c 2.2 0.330a
No temporal lobe cysts 82 (90.1) 53 (64.6) 3.9
Only parietal lobe cysts 11 (13.8) 10 (90.9) 0.019c 4.7 0.311a
No parietal lobe cysts 69 (86.2) 35 (50.7) 3.1
Only occipital lobe cysts 5 (4.4) 4 (80.0) 0.389c 6.5 0.475a
No occipital lobe cysts 109 (95.6) 61 (56.0) 0.5
Only basal ganglia and internal capsule cysts 2 (1.7) 1 (50.0) 1.000c 2.0 0.920a
No basal ganglia and internal capsule cysts 118 (98.3) 71 (60.0) 3.8
a Mann–Whitney test.
b Kruskal–Wallis test.
c Fisher’s exact test.
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Table 2
Adjusted logistic regression models looking at patient’s gender, age, and presence of any cysts in the specified phase and location as predictors of seizure.
Variable OR 95% confidence interval p-value for crude model
Defining cyst phase and location as non-mutually exclusive indicators for the presence of any cysts in the specified phase or location (n=153)a
Genderb 1.4 0.6–3.4 0.464
Age 3–24c 12.6 2.0–78.6 0.007
Age 25–34c 2.2 0.6–7.9 0.216
Age 35–44c 1.2 0.4–3.8 0.776
Age 45–54c 2.8 0.8–9.9 0.111
Presence of active cysts 0.4 0.1–1.3 0.123
Presence of transitional cysts 1.4 0.5–4.1 0.556
Presence of clusters 1.0 0.3–3.7 0.966
Presence of calcified cysts 0.8 0.3–2.4 0.684
Presence of parenchymal cysts 6.1 1.2–31.2 0.030
Presence of subarachnoid cysts 0.3 0.1–0.8 0.020
Presence of intraventricular cysts 0.5 0.1–2.1 0.334
Total number of cysts 1.1 1.0–1.2 0.028
Income<$70 per month 1.3 0.5–3.2 0.590
Distance of residence from paved road (km) 1.0 0.9–1.0 0.230
Residence in same province as treating hospital 0.5 0.2–1.4 0.191
Type of scan (CT or MRI)d 1.2 0.4–3.6 0.695
Defining cyst phase and location as mutually exclusive dummy variables indicating having only cysts in the specified phase or location (n=153)a
Genderb 1.3 0.6–3.1 0.529
Age 3–24c 7.5 1.4–39.4 0.018
Age 25–34c 2.0 0.6–6.6 0.285
Age 35–44c 1.1 0.4–3.4 0.860
Age 45–54c 2.1 0.6–7.0 0.242
Only active cysts (reference) – – –
Only transitional cysts 3.7 0.9–14.8 0.065
Only clusters 0.5 0.1–3.9 0.541
Cysts in multiple phases 1.0 0.3–3.4 0.964
Only parenchymal cysts 3.9 1.5–9.9 0.005
Only extraparenchymal cysts (reference) – – –
Cysts in both parenchymal and extraparenchymal locations 4.5 0.3–67.5 0.273
Total number of cysts 1.1 1.0–1.2 0.015
Income<$70 per month 1.2 0.5–2.7 0.737
Distance of residence from paved road (km) 1.0 1.0–1.0 0.991
Residence in same province as treating hospital 0.6 0.2–1.5 0.257
Type of scan (CT or MRI)d 1.4 0.6–3.5 0.447
a Adjusted model excludes those with too many cysts to count.
b Reference group is male.
c Reference group is patients 55–82 years old.
d Reference group is CT scan.
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individual patient was the same for 45 patients, while 18 patients
reported multiple seizures that, based on the patients’ description,
fit into differing ILAE classifications. The majority of patients with
seizures experienced partial seizures with secondary generaliza-
tion (41.1%), followed by generalized seizures (37.4%), simple
partial seizures (13.1%), non-specified partial seizures (4.7%), and
finally complex partial seizures (3.7%).
Men and women differed significantly in terms of the distribu-
tion of seizure classification (p = 0.040). Women had more partial
seizures without generalization (non specified, simple, and com-
plex) thanmen,whilemenhadmorepartial seizureswithsecondary
generalization and generalized seizures. In fact, all the complex
partial seizures were reported by women. Upon limiting the
comparison to generalized seizures and partial seizures with
secondary generalization, the seizure types for which selection bias
is less likely, thehigherproportionofmenwithinbothclassifications
was not statistically significant (p = 0.428) (data not shown). There
was no significant age difference in seizure classification (p = 0.680).
Looking at the 105 patients with seizures for whom we have a
baseline scan, seizure classification differed significantly among
patients with transitional cysts and parenchymal cysts, who were
more likely to have partial seizures with secondary generalization
(p = 0.003 and p = 0.035 respectively). None of the other cyst
characteristics (location or phase) were significantly associated
with the seizure classification. We had too few patients within
each category of seizure type formultivariate regressionmodeling.4. Discussion
We found that the proportion of patients with seizures in the
youngest age category (3–19 years) was much higher, at 100%,
compared with patients in all other age groups (between 50% and
63%). This association held in the regression model controlling for
gender, location and phase of the cysts, total number of cysts as
well as measures of healthcare access. Similar age differences
among NCC patients have been previously reported.27 While this
higher proportion of patients with seizure in the youngest age
group may be due, at least in part, to selection bias, as small
children may be taken to the hospital for diagnosis and treatment
only when they have obvious signs of illness such as seizures, in
our study, half of the 20 patients in the youngest age categorywere
between 15 and 19 years old. Onemight expect patients in this age
range to be able to communicate less observable symptoms aswell
as adults over 20 years old. Meanwhile, most of the seizures in
patients in the youngest age category appear to be provoked or
acute symptomatic seizures due to transitional cysts in the brain
parenchyma rather than new onset idiopathic epilepsy as most of
the patients in this group had transitional parenchymal cysts. Thus
it appears that children are more likely to have NCC-related
seizures than adults. There seems to be a similar phenomenon in
the traumatic brain injury literature. The probability of having
acute symptomatic seizure following head trauma is much higher
in children than in adults, even after controlling for severity of the
trauma.28–30
Table 3
Number (percent) of patients with specified type of seizure by patient gender, age and phase and location of cysts.
Number of patients with
seizures who had cysts in
specified location (% of total
with seizures)
Partial
not
specified
Simple
partial
Complex
partial
Partial w/
secondary
generalization
Generalized p-value
for Fisher’s
exact test
Total 107 (100) 5 (4.7) 14 (13.1) 4 (3.7) 44 (41.1) 40 (37.4)
Patient characteristics
Male 59 (55.1) 2 (3.4) 5 (8.5) 0 (0.0) 29 (49.2) 23 (39.0) 0.040
Female 48 (44.9) 3 (6.2) 9 (18.8) 4 (8.3) 15 (31.2) 17 (35.4)
Age 3–19 20 (18.7) 2 (10.0) 1 (5.0) 1 (5.0) 10 (50.0) 6 (30.0) 0.680
Age 20–29 20 (18.7) 1 (5.0) 3 (15.0) 1 (5.0) 6 (30.0) 9 (45.0)
Age 30–39 20 (18.7) 1 (5.0) 1 (5.0) 0 (0.0) 9 (45.0) 9 (45.0)
Age 40–49 25 (23.4) 1 (4.0) 7 (28.0) 1 (4.0) 8 (32.0) 8 (32.0)
Age 50–82 22 (20.6) 0 (0.0) 2 (9.1) 1 (4.5) 11 (50.0) 8 (36.4)
Cyst phase
Active 59 (56.2) 3 (5.1) 9 (15.3) 3 (5.1) 17 (28.8) 27 (45.8) 0.065
No active 46 (43.8) 2 (4.3) 5 (10.9) 1 (2.2) 26 (56.5) 12 (26.1)
Transitional 71 (67.6) 3 (4.2) 8 (11.3) 0 (0.0) 36 (50.7) 24 (33.8) 0.003
No transitional 34 (32.4) 2 (5.9) 6 (17.6) 4 (11.8) 7 (20.6) 15 (44.1)
Clusters 9 (8.6) 0 (0.0) 1 (11.1) 2 (22.2) 3 (33.3) 3 (33.3) 0.145
No clusters 96 (91.4) 5 (5.2) 13 (13.5) 2 (2.1) 40 (41.7) 36 (37.5)
Calcifications 45 (42.9) 3 (6.7) 8 (17.8) 2 (4.4) 15 (33.3) 17 (37.8) 0.547
No calcifications 60 (57.1) 2 (3.3) 6 (10.0) 2 (3.3) 28 (46.7) 22 (36.7)
Cyst location
Subarachnoid 30 (28.6) 1 (3.3) 5 (16.7) 2 (6.7) 12 (40.0) 10 (33.3) 0.809
No subarachnoid 75 (71.4) 4 (5.3) 9 (12.0) 2 (2.7) 31 (41.3) 29 (38.7)
Intraventricular 7 (6.7) 0 (0.0) 1 (14.3) 0 (0.0) 1 (14.3) 5 (71.4) 0.375
No intraventricular 98 (93.3) 5 (5.1) 13 (13.3) 4 (4.1) 42 (42.9) 34 (34.7)
Parenchymal 99 (94.3) 5 (5.1) 13 (13.1) 2 (2.0) 42 (42.4) 38 (37.4) 0.035
No parenchymal 6 (5.7) 0 (0.0) 1 (16.7) 2 (33.3) 1 (16.7) 2 (33.3)
Frontal lobe 67 (63.8) 3 (4.5) 9 (13.4) 0 (0.0) 29 (43.3) 26 (38.8) 0.123
No frontal lobe 38 (36.2) 2 (5.3) 5 (13.2) 4 (10.5) 14 (36.8) 13 (34.2)
Temporal lobe 52 (49.5) 3 (5.8) 8 (15.4) 1 (1.9) 15 (28.8) 25 (48.1) 0.062
No temporal lobe 53 (50.5) 2 (3.8) 6 (11.3) 3 (5.7) 28 (52.8) 14 (26.4)
Parietal lobe 70 (66.7) 4 (5.7) 11 (15.7) 1 (1.4) 28 (40.0) 26 (37.1) 0.401
No parietal lobe 35 (33.3) 1 (2.9) 3 (8.6) 3 (8.6) 15 (42.9) 13 (37.1)
Occipital lobe 44 (41.9) 4 (9.1) 7 (15.9) 0 (0.0) 19 (43.2) 14 (31.8) 0.158
No occipital lobe 61 (58.1) 1 (1.6) 7 (11.5) 4 (6.6) 24 (39.3) 25 (41.0)
Basal ganglia and I internal capsule 34 (32.4) 3 (8.8) 4 (11.8) 1 (2.9) 10 (29.4) 16 (47.1) 0.275
No basal ganglia and internal capsule 71 (67.6) 2 (2.8) 10 (14.1) 3 (4.2) 33 (46.5) 23 (32.4)
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patients having seizures, we did find a difference in the
classification of seizure, with women reporting more partial
seizures without secondary generalization and men reporting
more generalized seizures and partial seizures with secondary
generalization. This may represent a biological difference in NCC-
related seizures, or it could be due to reporting or selection bias.
The fact that there was no significant gender difference when
limiting the analysis to seizures with generalization (partial
seizures with secondary generalization and generalized seizures)
may indicate that selection bias has played a role, with women
seeking caremore frequently for the less disruptive partial seizures
without secondary generalization than men.
As with previous studies,3,15,17–21 we found that patients with
cysts in the brain parenchyma were more likely to have seizures,
even after controlling for patient age, gender, cyst phase and total
number of cysts. Patients with cysts in the parietal lobe and with
cysts in the frontal lobe were also more likely to present with
seizures compared to patients with cysts in other locations,
although the association for frontal lobe cysts was only significant
when limiting the comparison to those with only frontal lobe cysts
verses those without. These associations are as would be expected
from the literature.23 However, the association of seizures with
cysts in the occipital lobe has not been previously described in the
literature and may warrant further study.
The literature describes seizures as being caused by cysts in all
phases of evolution.4,12 While we found transitional cysts to be
associated with a significantly higher probability of seizure in the
chi-square analysis (Table 1), in the regressionmodels that adjusted
for patient age and gender aswell as the number and location of thecysts, no specific cyst phasewas found to be significantly associated
with having seizures (Table 2) and thus this lack of association after
adjustment appears to be consistent with the literature.4,12
However, anecdotal reports suggest that transitional cysts may be
a more common cause of seizures than cysts in other phases. Our
adjusted regressionmodels donot support this. It is possible that the
association of transitional cysts with seizure that some assume
based on observation could be due, at least in part, to the fact that
patients with transitional cysts are more likely to have cysts in the
parenchymal region of the brain (95.1% of those with transitional
cysts had parenchymal cysts versus 73.5% of those without
transitional cysts, p > 0.001). Having parenchymal cysts was found
in our models to be a strong (OR = 6.1) predictor of having seizures,
independentof thephaseof thosecysts. Inaddition, peoplewithNCC
cysts in the transitional phase are reportedly more likely to
experience symptoms in general compared to those with cysts in
other phases.31 Thus transitional cysts may be associated with all
symptoms, not just seizures, and since all the patients in our sample
were symptomatic,wewouldbeunablefindanassociationbetween
transitional cysts and any specific symptom. Finally, we must note
that in theadjusted logistic regressionmodel, thosewith transitional
did have a higher odds of seizures compared to those without
transitional cysts (OR = 1.4 when looking at the odds of seizure
among those with any transitional cysts versus those without and
OR = 3.7 when comparing the odds of seizure in those with only
transitional cysts versus those with only active cysts). It is possible
that having transitional cysts is associated with some increased
probability of seizure but we were underpowered to detect that
difference. Additional studies with larger samples of NCC patients
would be needed to assess whether patients with cysts in any
E.A. Kelvin et al. / Seizure 20 (2011) 119–125 125specific phase are trulymore likely to experience seizures. However,
it should be noted that some patients with only cysts in each phase
(active, transitional, and clusters) experienced seizures, and
therefore it seems that having cysts in any phase can cause seizures,
not just cysts in the transitional phase.
The distribution of seizure type in our populationwas consistent
with what is described in the literature,4,12,14,15,23 with generalized
seizures andpartial seizureswith secondary generalization beingby
far themost commontype, andcomplexpartial seizures occurring in
only 4 patients.We found that half of our patients (52%) had at least
one cyst in the temporal lobe and more than half of these patients
(59%) had seizures (Table 1). Meanwhile, only one of the 4 patients
with complex partial seizures had a cyst in the temporal lobe, while
of the other 3 patients, one had cysts in the parietal lobe, one had
cysts in the occipital lobe, and the last had cysts in the basal ganglia
and internal capsule. Thus the hypothesis that the rarity of complex
partial seizures is due to the low frequency of NCC cysts in the
temporal lobe23 is not supported by our data.
This studyhadanumberof limitations that shouldbeconsidered.
First, some cysts might not be identified at baseline due to edema,
and there might be some misclassification of location and phase of
evolution for those cysts that were identified. While our inter-rater
reliability was generally good, it was not perfect and thus some
misclassification occurred in determining cyst phase and location.
Anothermethodological challenge in our study is that seizureswere
classified based on patient description rather than observation.
Therefore, our resultsmight be influenced by reporting and/or recall
bias. We might expect poor recall to cause partial seizures with
secondary generalization to bemisclassified as generalized seizures
disproportionately as the initial partial seizure may not have been
noticed or may beminimized during the reporting compared to the
generalized portion of the seizure. In addition, we conducted a
numberof statistical tests, and therefore someof theassociationswe
found could be due to chance. We also had small numbers within
certain categories, and therefore we were under-powered for
investigating some associations. For example, only 17 patients
had intraventricular cysts, only 29 had clusters, and the number of
patients by seizure classification gets very small (sample size range
of 4–43). In addition, our youngest age category of 3–19 years
included only 20 patients and as those patients were homogeneous
in symptom, all havinghad seizures,wehad toexpand the age group
to 3–24 years for the regression model in order to have sufficient
variation in the outcome for effect estimation.
In this studywecomparedNCCpatientswhoexperienced seizures
to those who experienced other symptoms in terms of patient and
cyst characteristics. Larger sample sizes and improved sensitivity and
specificity of CT and MRI scan readings might make the relationship
between seizures and cyst characteristics clearer. Future research
should work on reducing and quantifying misclassification of scan
readings, perhaps by combining the readings of multiple neuror-
adiologists into a consensus reading. While we controlled for
measures of healthcare access in the multivariate regressionmodels,
other biases, such as selection, reporting and recall bias, may have
played a role in our study and should beminimized and evaluated in
the future.Also replicationof ourfindings is needed to rule out chance
as an explanation. Despite these methodological challenges, we did
find some associations that are a start toward identifying some of the
factors involved in explaining NCC-associated seizures.
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